Caxton Associates LP Has $642,000 Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Caxton Associates LP boosted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 100.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 30,767 shares of the company’s stock after buying an additional 15,453 shares during the quarter. Caxton Associates LP’s holdings in Nurix Therapeutics were worth $642,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new position in Nurix Therapeutics during the second quarter valued at approximately $601,000. Fred Alger Management LLC acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $794,000. Samlyn Capital LLC acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $12,177,000. Farallon Capital Management LLC acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $2,271,000. Finally, Integral Health Asset Management LLC acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $3,130,000.

Wall Street Analysts Forecast Growth

NRIX has been the subject of a number of recent analyst reports. Needham & Company LLC cut their price objective on Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, July 12th. Robert W. Baird initiated coverage on Nurix Therapeutics in a research report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, June 5th. JPMorgan Chase & Co. lifted their price target on Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, Barclays lifted their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Insider Activity

In other news, insider Christine Ring sold 5,760 shares of Nurix Therapeutics stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.81, for a total value of $119,865.60. Following the transaction, the insider now owns 19,838 shares in the company, valued at approximately $412,828.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, insider Gwenn Hansen sold 3,408 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the transaction, the insider now owns 45,150 shares in the company, valued at approximately $933,250.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.81, for a total value of $119,865.60. Following the sale, the insider now owns 19,838 shares in the company, valued at approximately $412,828.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,815 shares of company stock worth $1,416,751. Insiders own 7.20% of the company’s stock.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $23.21 on Friday. The stock’s fifty day moving average price is $23.10 and its two-hundred day moving average price is $18.54. Nurix Therapeutics, Inc. has a one year low of $4.22 and a one year high of $26.31. The firm has a market cap of $1.49 billion, a PE ratio of -7.95 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The company had revenue of $12.09 million for the quarter, compared to the consensus estimate of $19.35 million. Sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.